Radius is committed to putting patients first and ensuring that patients have affordable access to our therapies.
This is precisely why since launch, TYMLOS® (abaloparatide) injection has been priced approximately 50 percent less than the other product in its class, which may directly lower out-of-pocket costs for patients.
The current U.S. healthcare system wrongly incentivizes high drug list prices to the detriment of patients, particularly Medicare patients. We must work collaboratively across manufacturers, government, suppliers, PBMs and insurers, to improve the U.S. healthcare system and ensure patients are able to get their medicine when they need it. Radius supports the Department of Health and Human Services in its efforts to enact policies to tackle the barriers to more affordable drug coverage.
TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.